Case Review: Unresectable Metastatic Gastric Cancer


Daniel Catenacci, MD:My initial impression of this case is that it is a typical presentation for gastric cancer, presenting with vague symptoms: fatigue, anorexia, some weight loss, and mild abdominal pain. Eventually the patient gets worked up to have an upper endoscopy and is found to have a mass in the distal stomach; confirmed to be a stomach cancer. Ultimately with staging of CT scans and other blood tests, it’s determined that it’s metastatic stage 4 to the liver.

After typical staging and discussing the prognosis with the patient, that it’s an incurable cancer in the stage 4 setting, the patient received standard first-line chemotherapy. There are a number of different chemotherapy regimens available, all with phase III data to support their use; various 2-drug and 3-drug regimens. Though recently, FOLFOX chemotherapy has emerged as a preferred standard therapy, which is what this patient received. Also, what we would expect, most patients derive some clinical benefit and palliation from this chemotherapy, with a response rate of approximately 40%, and another 40% of patients having at least disease control.

This patient, at the first imaging time point at 3 months, demonstrated that there was a response on imaging and was doing well with therapy. Unfortunately, and also as expected, by 7 months into treatment, the patient demonstrated progression, and that is a typical median progression-free survival on most studies.

At that time point, the patient was assessed and had a preserved performance status, and so she appropriately was offered second-line therapy. Typically, there is, again, a number of options for chemotherapy in the second-line setting—irinotecan-based, taxane-based. Most recently, there was a large phase III study, called the RAINBOW study, which was assessing paclitaxel with ramucirumab, compared to the control of paclitaxel alone; this demonstrated an improved overall survival, as well as a response rate. So, this patient received paclitaxel with ramucirumab; that’s where the patient was in terms of when we left off with their case.

Transcript edited for clarity.

A 61-Year-Old Woman With Stage 4 Gastric Cancer

November 2017

  • A 61-year-old Hispanic woman presents to her PCP complaining of unexplained weight loss (15 lbs over 6 months), intermittent abdominal pain, fatigue, and recent onset of vomiting
  • BMI: 23
  • PE: negative for ascites
  • Notable laboratory findings:
    • HB: 11.2 g/dL
    • LFT: WNL
    • GFR: 100
    • CEA, 18.4 ng/mL
    • AFP, CA 19-9, and CA 125: WNL
  • Upper gastric endoscopy: suspicious 7.2-cm ulcerative lesion involving the pyloric region
  • Endoscopic ultrasound: suspicious lymph node
  • Biopsy: confirmed poorly differentiated, gastric adenocarcinoma, diffuse histologic subtype; positive lymph node
  • Molecular testing: HER2(-), MSI-stable, PD-L1 expression 0%
  • CT of chest, abdomen, and pelvis: showed diffuse invasion of the gastric wall and visceral peritoneum, lymph node involvement, 1 hepatic lesion
  • Staging: stage IV gastric adenocarcinoma, unresectable
  • ECOG PS 0

January 2018

  • The patient was started on fluorouracil and oxaliplatin (FOLFOX)
  • Follow up CT at 3 months showed a response to systemic therapy

July 2018

  • Patient reports increasing nausea, fatigue, and shortness of breath
  • CT imaging at 7 months shows metastatic spread to multiple suprapyloric nodes and a new liver lesion
  • LFT: mildly elevated; GFR: WNL; HB: 10.8 g/dL
  • ECOG PS 1
  • Patient is motivated to try another systemic therapy
  • Treatment with paclitaxel/ramucirumab is planned
Related Videos
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Mark A. Lewis, MD, with the Oncology Brothers presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content